EUVIMEDEUVIMED entdecken
Crossref

Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma

Xiaoqin Li, Hang Xu, Rujun Hong, Haitao Yang, Lihuan Xu, Guanying Zheng, Baosong Xie

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xiaoqin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Critical Care Medicine, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, …. Hauptthemen laut MEDLINE: Pemetrexed, Cisplatin, Lung Neoplasms, T-Lymphocytes. Die Arbeit nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of neoantigen-reactive T cells (NRT) therapy in solid tumors, encompassing aspects such as infiltration, recognition, cytotoxicity, and enduring persistence, is notably influenced by the immunological microenvironment. This study endeavors to investigate whether the co-administration of pemetrexed and cisplatin augments the therapeutic efficacy of NRT therapy in lung cancer. Neoantigens were predicted using a comprehensive analysis of mutation data from Lewis lung carcinoma cells and mouse tail tissues. The immunogenicity of NRT cells was assessed through flow cytometry and IFN-γ ELISpot assays. A mouse model of NSCLC was used to investigate the anti-tumor effects of NRT combined with chemotherapy. The combination of NRT cells and chemotherapy significantly inhibited tumor growth in a mouse model, increased CD3+/CD137+ T cells to promote IFN-γ secretion from NRT cells, and up-regulated the levels of inflammatory cytokine proteins including IFN-γ, TNF, IL-6 and IL-10. Immunofluorescence analysis confirmed increased T-cell infiltration in tumor tissues without adverse effects on vital organs. In addition, transcriptome analyses indicated that the tumor microenvironment was altered to favor M1-like macrophages with an increased M1/M2 ratio, creating a pro-inflammatory environment. The integration of NRT with frontline chemotherapy for lung cancer could yield profoundly ideal therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemetrexedCisplatinLung NeoplasmsT-LymphocytesCarcinoma, Lewis LungAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungAnimalsMiceTumor MicroenvironmentMice, Inbred C57BLDisease Models, AnimalCell Line, TumorAntigens, NeoplasmHumansCytokinesFemaleAntineoplastic Agents

Stichwörter der Autor:innen

ChemotherapyCisplatinLung cancerNeoantigen-reactive T-cellPemetrexed

Substanzen

PemetrexedCisplatinAntigens, NeoplasmCytokinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Critical Care Medicine, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou Fujian China.
  • Department of Respiratory Medicine and Critical Care Medicine, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou Fujian China.…

Zitieren

APA

Li, X., Xu, H., Hong, R., Yang, H., Xu, L., Zheng, G., & Xie, B. (2025). Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114174

Vancouver

Li X, Xu H, Hong R, Yang H, Xu L, Zheng G, et al. Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114174

BibTeX
@article{Li2025,
  author = {Li, Xiaoqin and Xu, Hang and Hong, Rujun and Yang, Haitao and Xu, Lihuan and Zheng, Guanying and Xie, Baosong},
  title = {Frontline pemetrexed and cisplatin based-chemotherapy combined with NRT promoted the antitumor in a mouse model of lung carcinoma},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114174}
}
Kostenlos starten →